Although metabolic reprogramming within the tumour microenvironment (TME) has been reported in breast cancer, whether and how this evolves during treatment remains unclear. Here, the authors use multiple ‘omic’ analyses to examine this question in patients with breast cancer undergoing neoadjuvant chemotherapy.
- Kang Wang
- Ioannis Zerdes
- Theodoros Foukakis